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Herpesvirus glycoprotein C (gC) functions as a major virus attachment protein. The gC sequence of the neurovirulent 
bovine herpesvirus type 5 (BHV-5) virus was determined and compared with the gC sequence of the nonneurovirulent BHV- 
1. Alignment of the predicted amino acid sequences of BHV-1 and BHV-5 gC ORFs showed that the amino-terminal third 
of the protein differed between the two viruses. Whole or subgenomic fragments of gC coding regions from both viruses 
were expressed as trpE-gC fusion proteins in Escherichia coil to map linear epitopes defined by type-specific murine 
monoclonal antibodies (MAbs). Based on the reactivity of BHV-l-specific MAbs with the recombinant proteins, two epitopes 
were mapped between BHV-1 gC residues 22 and 172. Unidirectional deletion f these residues at the carboxy end mapped 
one within residues 22-69  and the other within residues 103-122. Two BHV-5-specific MAbs identified an epitope coding 
region within BHV-5 gC residues 31-78. Bovine antisera against BHV-1 and BHV-5 showed specificity to BHV-1 gC residues 
22-69 and to BHV-5 gC residues 31-78, respectively, in a type-specific manner. © 1995 Academic Press, Inc. 
INTRODUCTION 
Bovine herpesvirus-1 (BHV-1) is associated with a vari- 
ety of clinical diseases including rhinotracheitis, conjunc- 
tivitis, genital infections, and occasionally abortion, enter- 
itis, encephalitis, and generalized systemic infections in 
cattle (Ludwig, 1983; Wyler etaL, 1989). BHV-1 strains fall 
into two different groups based on their DNA restriction 
profiles and pathogenic properties= the respiratory/ 
abortogenic group (infectious bovine rhinotracheitis vi- 
rus) and the nonabortogenic genital group (infectious 
pustular vulvovaginitis). The neurovirulent bovine herpes- 
virus (previously classified as BHV-1.3) has been reclas- 
sified recently as BHV-5 (Roizman eta/., 1992) and is 
known to cause epidemics of a uniformly fatal encephali- 
tis in calves (Carillo etaL, 1983a,b; French, 1962; Eugster 
eta/., 1974; Bartha eta/., 1969). Both the BHV-1 and the 
BHV-5 strains are neurotropic viruses, but they differ in 
their ability to cause encephalitis in calves (Belknap et 
a/., 1994). BHV-1 grows in higher titers in the respiratory 
epithelium compared to BHV-5 (Belknap eta/., 1994), but 
a glycoprotein C (gC)-deleted BHV-1 vaccine strain repli- 
cates less efficiently in the upper respiratory tract of cat- 
tle (Liang eta/., 1992). 
Herpesvirus glycoproteins are important for the inter- 
action of the virus with its host. The glycoproteins medi- 
ate infection of target cells and, thus, influence cell and 
tissue tropism and are also major antigens recognized 
bythe infected host's immune system (Babiuk eta/., 1987; 
Little et al., 1981; GIorioso et al., 1984; Herold eta/.,  
1991; Lupton and Reed, 1980). The alpha herpesviruses, 
including herpes simplex viruses (HSV-1, HSV-2), pseu- 
dorabies virus, and BHV-1, contain a number of function- 
ally and structurally homologous glycoproteins. Three 
major glycoproteins of BHV-1 (gB, gO, and gD, previously 
named gl, gill, and glV, respectively) are partially homolo- 
gous to HSV gB, gO, and gD, respectively. 
Bovine herpesvirus types 1 and 5 share 85% DNA ho- 
mology when the whole genome is compared (Engles et 
aL, 1987). However, the DNA restriction maps of BHV-1 
and BHV-5 are strikingly distinct (Engles et aL, 1987; 
Bulach and Studdert, 1990). This suggests that nucleo- 
tide sequence differences between these two viruses 
are distributed throughout the entire genome. Based on 
monoclonal antibody (MAb) reactivities, we and others 
have demonstrated antigenic differences between the 
major glycoproteins of these two viruses (Metzler et aL, 
1985, 1986; Friedli and Metzler, 1987; Collins eta/., 1993; 
Abdelmagid eta/., 1995). However, gC of these two vi- 
ruses was the most dissimilar (Collins et al., 1993). 
BHV-1 gC is a 180/97K dimeric glycoprotein. The pro- 
tein is important in the virus attachment process because 
purified gC inhibits BHV-1 attachment (Collins et al., 
1984; Marshall et aL, 1988; van Drunen Little-van den 
Hurk et aL, 1984; van Drunen Little-van den Hurk and 
Babiuk, 1986). BHV-1 gC consists of 521 amino acid (aa) 
residues that constitute a signal peptide between resi- 
dues 7 and 21, a projecting region, and the transmem- 
brane anchor domain between residues 467 and 500 
followed by a hydrophilic C-terminal region (Fitzpatrick 
et aL, 1989). Four potential N-linked glycosylation sites 
[Asn-X-Ser (Thr)] are present on the predicted amino acid 
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sequences of gC located at amino acids 93, 111, 164, 
and 208 (Fitzpatrick eta/., 1989). Based on competitive 
binding assays using gO-specific MAbs, one unique and 
four interrelated antigenic areas of BHV-1 gC were re- 
ported (Marshall eta/., 1988). Recently, three BHV-1 gC 
epitopes have been mapped between aa residues 22 
and 150 (Fitzpatrick eta/., 1990). However, the precise 
location of each of these three epitopes was not deter- 
mined. Two other epitopes were mapped between resi- 
dues 140-240 and 230-287 (Fitzpatrick eta/., 1990). 
The objectives of this study were to (i) analyze the 
genetic basis of antigenic differences between the gC 
genes of nonneurovirulent/respiratory BHV-1 and neuro- 
virulent BHV-5 viruses and (ii) identify and analyze sev- 
eral BHV-1 gO- and BHV-5 gO-specific epitopes located 
along the gO coding region. The BHV-5 gO sequence was 
determined and compared with the BHV-1 gO sequence. 
DNA fragments containing the whole and partial se- 
quences of BHV-1 and BHV-5 gO coding regions were 
expressed as trpE-gC fusion proteins in Escherichia 
coil BHV-1 and BHV-5 gO-specific MAbs were reacted 
to respective fusion proteins by Western immunoblotting, 
and the precise locations of two BHV-l-specific and one 
BHV-5-specific linear epitopes were determined by ana- 
lyzing MAb reactivity. 
MATERIALS AND METHODS 
Virus strains and cell lines 
The Cooper (Colorado-I) strain of BHV-1 was obtained 
from the American Type Culture Collection (Rockville, 
MD). The TX-89 strain of BHV-5 (isolated from a case of 
viral encephalitis) (d'Offay eta/., 1993) was provided by 
Dr. d'Offay from Oklahoma State University. The two vi- 
ruses were propagated and titrated in Madin-Darby bo- 
vine kidney cells grown in Dulbecco modified Eagle's 
medium supplemented with 10% fetal bovine serum. 
Monoclonal and polyclonal antibodies 
MAbs F2 and 24 are specific for BHV-1 gO (Ab- 
deimagid et aL, 1993; Collins et a/., 1993). They neutral- 
ized BHV-1 but not BHV-5 in the presence of complement 
(Collins eta/., 1993; S. I: Chowdhury, unpublished data). 
MAbs 8B1 and L6G are BHV-5 gO specific but are non- 
neutralizing (Abdelmagid eta/., 1993; Ohung eta/., 1994). 
MAbs 24 and 8B1 were provided by Dr. H. Minocha of 
Kansas State University. MAbs F2 and L6G were ob- 
tained from Dr. J. Collins, Colorado State University. 
Monospecific bovine anti-BHV-1 and anti-BHV-5 sera 
(Collins eta/., 1993) were obtained from Dr. Whetstone, 
National Animal Disease Center, USDA. 
Mapping, cloning, and sequencing of the BHV-5 gC 
gene 
The location of the gO gene on the BHV-5 genome 
and pertinent restriction sites for the subcloning and the 
sequencing strategy are illustrated in Fig. 1. A pUC- 
based plasmid library containing the BamHI genomic 
fragments of the BHV-5 genomic DNA was developed. 
To verify the general location of the BHV-5 gC gene, the 
1.7-kb BamHI-Afll l l  subfragment, carrying the gC gene 
sequences of BHV-1, was subcloned from the Hindlll I 
fragment of BHV-1 DNA (Mayfield eta/., 1983). The above 
cloned DNA was labeled with 32p by nick translation 
(Sambrook eta/., 1989) and used as a probe for hybridiza- 
tion (Chowdhury eta/., 1988) with the 18.95-kb BamHI A 
fragment of BHV-5 (Engles eta/., 1987; Bulach and Stud- 
deft, 1990). To precisely map the BHV-5 gC gene, the 
BamHI A fragment was digested further with several re- 
striction endonucleases, separated on agarose gels, and 
analyzed by hybridization with the same probe. Based 
on the hybridization results, a 1.72-kb BamHI-Afll l l  frag- 
ment (m.u. 0.135-0.125) was identified and cloned. A 
restriction map of the cloned 1.72-kb fragment was con- 
structed, and subclones spanning the entire fragment 
were generated. Both strands of each fragment were 
sequenced by Sanger's dideoxy chain termination 
method (Sanger eta/., 1977) and verified by the method 
of Maxam and Gilbert (1977; Chowdhury eta/., 1990). 
Sequence analysis 
DNA sequence data were assembled and analyzed 
using the Seqaid II sequence analysis software (D. D. 
Rhodes and D. J. Roufa, Center for Basic Cancer Re- 
search, Kansas State University, Manhattan). The pre- 
dicted amino acid sequences of BHV-5 gC (this study) 
and BHV-1 gC (Fitzpatrick et al., 1989) were aligned by 
using Multalin software (Corpet, 1988). Hydropathicity 
analyses were performed (Kyte and Doolittle, 1982) using 
a nine-aa window, and the antigenicity profiles of pre- 
dicted aa sequences were analyzed using the Seqaid II 
softwa re. 
Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western blot 
analysis 
SDS-PAGE of mock- and virus-infected cell proteins 
or bacterially expressed fusion proteins was performed 
under reducing conditions as described earlier (Laemmli, 
1970; Abdelmagid et al., 1995). 
Construction of recombinant plasmids 
The 1.7-kb BamHI/Afllll (blunt) fragment containing the 
whole BHV-1 gC ORF (Fitzpatrick etaL, 1989) was cloned 
into the BamHI/Smal site of a pATH 23 plasmid (Koerner 
et aL, 1991) to yield an inframe trpE-BHV-1 gC fusion 
gene (plasmid clone plgC1-521). The recombinant plas- 
mid was used to transform E. coil RR1 cells. A clone 
containing the BHV-1 gC coding sequences (verified by 
sequencing) was selected and tested for gC expression 
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FIG. 1. The BamHI restriction site map of BHV-5 DNA and the cloning and sequencing strategies of BHV-5 gC gene. The genomic organization 
of BHV-5 (TX-89 strain), depicted on top, consists of unique long (UL) and short (Us) regions and two repeat regions (IR and TR). The BamHI restriction 
endonuclease map was described originally for the N569 strain of BHV-5 by Engles et aL, 1987. The gC gene of BHV-5 was mapped to the BamHI 
A (18.95 kb) genomic fragment between m.u. 0.02 and 0.135 and then to the BamHI/Afllll fragment (1720 bp) between m.u. 0.125 and 0.135 by 
subcloning and hybridization with radiolabeled BHV-1 gC gene DNA probe. A restriction site map of the BamHI/Afllll (1720 bp) fragment was 
generated, and various restriction endonuclease subfragments, indicated as bold lines, were cloned and sequenced. The arrow represents the 
BHV-5 gC ORF, which is 1415 nucleotides long starting with the ATG codon and terminating with TAG. The arrow shows the direction of transcription. 
(described below). All subsequent clonings and manipu- 
lations spanning portions of the BHV-1 gC open reading 
frame (ORF) were generated either directly or indirectly 
from this clone. The 1.01-kb BamHI/Xhol fragment con- 
taining the first 300 aa of BHV-5 gC (Fig. 2) was inserted 
into the BamHI/Sall site of a pATH 22 plasmid (Koerner 
et al., 1991) to yield an inframe trpE-BHV-5 gC fusion 
gene and cloned by transforming E. coli RR1 cells. A 
clone (plasmid clone p5gC1-300) containing the BHV- 
5 gC coding sequences (verified by sequencing) was 
selected, and the specificity of the induced fusion protein 
to a BHV-5 gC-specific MAb (MAb 8B1) was tested (see 
Results). All subsequent clonings containing portions of 
the BHV-5 gC ORF were generated either directly or indi- 
rectly from this clone. 
Construction of plgC1-336. Plasmid plgC1-521 was 
digested with Xhol and treated with Klenow enzyme. The 
DNA was redigested with BamHI, and the 1.16-kb frag- 
ment was gel purified and cloned into BamHI/Smal-di- 
gested pATH23 plasmid. 
Construction of plgC1-172. Plasmid plgC1-336 was 
digested with Sstl, and the larger fragment was purified 
and religated. The resulting plasmid contain the BamHI/ 
Sstl fragment coding the N-terminal 172 aa of BHV-1 gC. 
Construction ofp 1gC173-336. Plasmid pl gC1-336 was 
digested with Sstl, and the 500-bp fragment was purified 
and cloned into the Sstl site of the pATH22 plasmid. A 
clone containing the BHV-1 gO residues 173-336 in cor- 
rect orientation (verified by sequencing) was selected. 
Construction of p l gC 1-122, p l gC 1-103, and p l gC 1-69. 
These plasmids were obtained by unidirectional deletion 
at the 3' end of gC coding sequences contained within 
the plasmid clone plgC1-172. To facilitate unidirectional 
deletion, the Xbal/EcoRI fragment of plgC1-172 flanking 
the BamHI/Sstl sites of insert was first cloned into the 
Xbal/EcoRI sites of pGEM 7Z (clone p7ZgC1-172). Then 
unidirectional deletions were introduced at the EcoRI site 
following the protocol for exonuclease III at 30 ° (Erase- 
a-Base system; Promega). Samples were taken at 1-min 
intervals and processed further following the manufactur- 
er's instruction. Following ligation, several deleted plas- 
mids were used to transform E. col~ DH5a cells. Clones 
containing deletions were screened, and several clones 
were sequenced to determine the extent of the deletions. 
Based on the sequences, three clones (p1.1, p2.2, and 
p3.7 with 151-, 208-, and 310-bp deletions with respect 
to the Sstl site of p7ZgC1-172) were selected for further 
cloning into the pATH23 vector. Plasmids p1.1, p2.2, and 
p3.7 were digested with Xbal/Sstl. The 530-, 470-, and 
370-bp fragments (p1.1, p2.2, and p3.7, respectively) were 
cloned into Xbal/Sstl-digested pATH23 plasmid to yield 
plgC1-122, plgC1-103, and plgC1-69, respectively. 
Construction of p5gC1-136. Plasmid p5gC1-300 was 
digested with Sstl, and a 520-bp fragment (Sstl site of 
pATH 22 is located immediately upstream of the BamHI 
site) was purified and inserted into the Sstl-digested 
pATH 22 plasmid (in correct orientation). 
Construction ofp5gCl-78. Plasmid pSgC1-136 was di- 
TYPE-SPECIFIC EPITOPES OF BHV-1 AND BHV-5 gC 561 
1 i0 20 30 40 50 60 
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. . . .  :::: : : : : 
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: : : : : : * :  : : : : : : : : : * : : :  : : : : : * : : : : : : : :  : : : : : : : : : :  : : : : : : : :  
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::: : : : : : : : : :  : : : : : : : : : : : :  : : : : : : : : :  : : : : : : : : : : : : : : : : : : : : :  
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: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :  
BHV-5 .gC TRLRWFRNGYPVEARHARDVFTVDDSGLFSRTSVLTLEDATPTAHPPNLRCEVSWFQSAD 
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BHV-5 .gC CAERPRLVNMRGVRLLSAIDGPVDYTCTATGYPAPLPEFSATATHDASPSL IGSPVIVSV 
• 390 400 • 420 430 440 
BHV- I .gC  
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• 460 470 
FIG. 2. Comparison of the predicted amino acid sequence of the BHV-5 gC with the predicted amino acid sequences of BHWl gC (Fitzpatrick 
et aL, 1989). The predicted amino acid sequences of the BHV-1 and BHW5 glycoproteins C were aligned by using Multalin software (Corpet, 1988). 
Amino acid numbering starts at the first methionine and is indicated for BHV-1 (top) and BHV-5 (bottom). Amino acids aligned identically between 
the two sequences are indicated by two dots, conservative substitutions are indicated by an asterisk, and conserved cysteine residues are marked 
by an arrowhead. Potential N-linked glycosylation sites are indicated (+++). The presumptive signal sequences and the transmembrane anchor 
sequences are shown by broken and solid lines, respectively. 
gested with Narl and treated with the Klenow enzyme. 
The DNA was redigested with Sstl, and a 350-bp frag- 
ment was purified and inserted into he Sstl/Smal-di- 
gested pATH22 plasmid. 
Preparation of usion proteins 
The synthesis of trpE-gC fusion proteins was induced 
in modified M9 medium by tryptophan starvation and 
indoleacrylic acid as described (Koerner eta/., 1991; Ab- 
delmagid eta/., 1995). 
RESULTS 
Identification of BHV-5 gC open reading frame and 
comparison of predicted aa sequences of BHV-5 and 
BHV-1 gC 
The nucleotide (nt) sequence of the BHV-5 gO gene 
has been deposited with the GenBank Database under 
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Accession No. U35883. The nucleotide sequence analy- 
sis of the 1.72-kb BamHI/Afllll fragment (m.u. 0.135- 
0.125) identified two potential start codon (ATG) se- 
quences situated close to each other at positions nt 69 
and nt 113. Translation initiation at nt 113 would result 
in a 1415-bp ORF coding for 470 aa residues (ORF1; Fig. 
2), large enough to encode the BHV-5 gO gene but 50 
aa shorter than the BHV-1 gC gene. However, translation 
initiation at nt 69 would result in a much shorter 641-bp 
ORF coding for only 213 aa (ORF2; data not shown). 
Alignment of BHV-5 gC ORF1 sequences with the corre- 
sponding sequences of BHV-1 (Fitzpatrick et aL, 1989) 
showed considerable homology (89.9%) at the carboxy- 
terminal two-thirds of the two proteins (aa 124-470 of 
BHV-5 gC); however, the amino-terminal third of the two 
proteins (aa 1-123 and aa 1-149 of BHV-5 and BHV-1 
gO, respectively) differed significantly (23.5% homology) 
(Fig. 2). Alignment of ORF2 sequences showed some 
homology of the first 40 aa but no obvious similarity to 
the rest of BHV-1 sequences (data not shown). To identify 
the BHV-5 gC as the product of the ORF1 sequences, 
the 1.01-kb BamHI/Xhol fragment containing the first 300 
aa was expressed as a trpE fusion protein in pATH22 
vector, and its reactivity to a BHV-5 gC-specific MAb, 8B1, 
was tested by immunoblotting experiments. The MAb 
reacted specifically to a 70K protein corresponding to 
the molecular weight of the fusion product (trpE, 37K; 
BamHI/Xhol, 32.26) (Fig. 3b). 
As in BHV-1, the predicted BHV-5 protein has 9 cys- 
teine residues, 8 of which are located in the putative 
external domain. The cysteine residue at aa 40 of BHV- 
1 gO did not align with cysteine residue at aa 47 of BHV- 
5 gC. However, 8 cysteine residues (aa 116, 254, 315, 
354, 358, 384, and 448 of BHV-5 gC), including the 6 
cysteine residues conserved in several ~ herpesviruses 
(Fitzpatrick etaL, 1989), aligned with the two sequences. 
Two potential N-linked glycosylation sites (Kornfeld and 
Kornfeld, 1985) located at aa 164 and 208 of BHV-1 gC 
are conserved, but two other potential glycosylation sites 
at aa 93 and 111 of BHV-1 gC are not present in the 
BHV-5 gC (Fig. 2). Hydropathic analysis of the predicted 
protein revealed the presence of two prominent hy- 
drophobic peaks similar to the BHV-1 gC, representing 
the signal sequence and the transmembrane anchor se- 
quence (Fig. 4). Based on empirical rules for predicting 
signal sequences (von Heinje, 1986), aa residues 14 to 
30 have the position, length, relative hydrophobicity, and 
consensus cleavage site characteristic of a signal se- 
quence. Similarly, aa residues 430 to 463 have the posi- 
tion, length, and relative hydrophobicity characteristics 
of a transmembrane anchor sequence (Figs. 2 and 4). 
The analysis also revealed that the relative hydrophilicity 
characteristics of aa 1-120 and aa 1-150 of BHV-5 gC 
and BHV-1 gC, respectively, showed some degree of 
divergence. However, with the exception of a shorter 
1 2 1 2 
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FIG. 3. Identification of BHV-5 gC ORF-specified protein. (A) Coomas- 
sie blue-stained SDS-PAGE gel containing (lane 1)trpE and (lane 2) 
trpE gO (BHV-5) aa 1-300 proteins and (B)immunoblotting of the same 
proteins with BHV-5 gC-specific MAb 8B1. The locations of (lane 1) 
trpE and (lane 2) trpE-gC(BHV-5) fusion proteins are indicated by ar- 
rowheads. 
carboxy-terminal hydrophilic region in the BHV-5 se- 
quence, located immediately downstream of the putative 
transmembrane domain, the rest of the sequences 
showed almost identical hydrophilicity profiles when 
aligned with the BHV-1 (Fig. 4). 
Further analysis of the amino-terminal sequence be- 
tween the two viruses show that there are more nega- 
tively charged residues within the first 149 aa of BHV-1, 
whereas the corresponding region of BHV-5 gC (aa 1-  
123) contained more positively charged aa. This was 
also true when the BHV-1 and BHV-5 sequences were 
analyzed without the signal sequences. Respectively, 
BHV-1 residues 22-149 had 12 glutamic acid, 5 aspartic 
acid, 10 arginine, and 3 lysine residues while the corre- 
sponding BHV-5 residues (31-123) had 3 glutamic acids, 
7 aspartic acids, 15 arginines, and 1 lysine (Fig. 2). 
Use of recombinant fusion proteins and virus-specific 
monoclonal antibodies to define epitope structure on 
the BHV-1 and BHV-5 gC glycoproteins 
The 37-kDa trpE protein (vector control) and the larger- 
sized trpE-gC fusion proteins, which were composed of 
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FIG. 4. Comparison of the hydropathicity plots of the amino acid sequences of BHV-1 and BHV-5 glycoproteins C. The BHV-5 and BHV-1 gC 
amino acid sequences were analyzed for hydropathicity characteristics (Kyte and Doolittle, 1982) using a nine-amino-acid window. The BHV-5 gC 
is shown on top, and the BHV-1 gC (Fitzpatrick et aL, 1989) is shown on the bottom. The hydropathic scores and the amino acid numbers are 
shown on the vertical and horizontal axes, respectively. 
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BHV-5  of var iab le  Length, are  shown in Figs. 5 and  7, 
respect ive ly .  The  induced  fus ion  pro te ins  conta in ing  
BHV-1 gC res idues ,  aa 1 -521  (data  not  shown) ,  aa 1 -  
336 (data not  shown) ,  aa 1 -172 ,  aa 1 -122 ,  aa 1 -103 ,  
and  aa 1 -69  were  represented  by p lgC1-521 ,  p lgC1-  
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FIG. 5. SDS-PAGE and immunoblotting analysis of trpE-gC (BHV-1) fusion proteins. (A) Coomassie blue-stained gel showing fusion proteins 
expressed by subfragments of gO (BHV-1) ORF using the pATH vector system. (Lane 1) trpE, (lane 2), BHV-1, and (lane 3) BHV-5 infected MDBK 
cell lysates; trpE-gC (BHV-1) proteins, (lane 4) 1-172, (lane 5) 1-122, (lane 6) 1-103, and (lane 7) 1-69. The locations of trpE (lane 1) and trpE- 
gO (BHV-1) fusion proteins (lanes 4-7) are marked with arrowheads. Immunoreactivity of the same proteins with (B) MAb 24 and (C) MAb F2. 
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FIG. 6. Schematic representation of the BHV-1 gC glycoprotein and its segments that were expressed in pATH vectors. The BamHI/Afllll fragment 
containing the gC (BHV-1) ORF is depicted on top, showing restriction endonuclease sites used for cloning into pATH plasmids. Glycoprotein C 
protein segments expressed are shown as solid bars identified by aa numbers. A summary of the immunoreactivity of gC (BHV-1) protein segments 
with MAbs 24 and F2 is shown on the table to the right, with (+) to denote reactivity and ( - )  for no reactivity. 
336, plgC1-172, plgC1-122, plgC1-103, and plgC1-69, 
respectively (Fig. 5A). Fragments containing the epitope- 
bearing sequences in the correct reading frames were 
recognized by the MAbs, thus localizing the epitope re- 
gion in the glycoprotein. The results of immunoblotting 
of these fusion proteins with two BHV-1 gC-specific 
MAbs are shown in Figs. 5B and 5C. In addition to the 
fusion proteins with predicted molecular weight, a num- 
ber of additional bands also were detected consistently 
by Western blotting. One xplanation for the presence 
of these bands is proteolytic degradation of exogenous 
proteins, which has been reported for E. coil  (McDonald 
et al., 1987). 
The reactivity of the fusion proteins with the MAbs and 
the location of the epitope-bearing segment on the BHV- 
1 gC ORF are summarized in Fig. 6. MAbs F2 and 24 
reacted to the fusion proteins expressing the aa residues 
1-521 (entire gO ORF; data not shown), 1-336 (data not 
shown), and 1-172 (N-terminal third) (Fig. 5) but not to 
the fusion protein expressing residues 173-336 (data 
not shown). This narrowed the location of epitopes to a 
stretch of 172 aa expressed by the BamHI/Sacl subfrag- 
ment (Figs. 5 and 6). Unidirectional deletions of residues 
1-172 at the carboxy end of the protein was used to 
generate progressively shorter proteins containing BHV- 
1 gO aa 1-122, aa 1-103, and aa 1-69. Mab F2 recog- 
nized all of these proteins, localizing the epitope between 
aa 1 and 69 (Fig. 5C). Because the mature form of BHV- 
1 gO probably lacks the signal sequence aa 1-21 (Fitzpa- 
trick et al., 1989), residues 22-69 are likely to contain 
an epitope recognized by the MAb F2 (Fig. 6). MAb 24 
(Fig. 5B) recognized fusion proteins containing gC aa 
residues 1-122 but did not react to aa residues 1-103 
and 1-69, indicating that the location of an epitope is 
between aa residues 104-122 (Fig. 6). 
Similarly, the induced fusion proteins containing BHV- 
5 gC residues aa 1-300, aa 1-136, and aa 1-78 (repre- 
sented by pSgC1-300, p5gC1-136, and p5gC1-78, respec- 
tively) were recognized by MAbs 8B1 (Figs. 7B and 8) 
and L6G (data not shown). Because the mature form of 
BHV-5 gO probably lacks the signal sequence aa 1-30 
(Fig. 2), residues 31-78 are likely to contain the epitope 
recognized by MAbs 8B1 and L6G. 
BHV-1- and BHV-5-specific bovine antiserum reacted 
specifically with fusion proteins containing respective 
type-specific epitope coding gC sequences 
Bovine serum raised against either BHV-1 or BHV-5 
whole virus was tested by immunoblotting for reactivity 
with recombinant fusion proteins containing BHV-1 gC 
aa residues 22-69 and BHV-5 gC aa residues 31-78. 
The results (data not shown) showed that anti-BHV-1 and 
anti-BHV-5 bovine serum reacted specifically with BHV- 
1 gC aa 22-69 or with BHV-5 gC aa 31-78 containing 
the respective type-specific antigen. To determine the 
binding specificity of bovine serum antibodies to fusion 
proteins, immunoblots containing the BHV-1 or BHV-5 
gC residues 22-69 and 31-78 were probed with these 
bovine sera that were absorbed with purified BHV-1 and/ 
or BHV-5 (Fig. 9). The bovine anti-BHV-5 antibody showed 
binding specificity to the BHV-5 gC (aa 31-78)-specific 
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FIG. 7. SDS PAGE and immunoblotting analysis of trpE-gC (BHV- 
5) fusion proteins. (A) Coomassie blue-stained gel showing fusion pro- 
teins expressed from BHV-5 gC ©RF in the pATH vector system, (Lane 
1) BHV-5-infected MDBK cell lysate, (lane 2) trpE, (lane 3) trpE-gC 
(BHV-5) aa 1-300, (lane 4) trpE-gC (BHV-5) 1-136, and (lane 5) trpE- 
gO (BHV-5) 1-78. (B) Immunoblotting of the same proteins with BHV- 
5-specific MAb 8B1. The locations of (lane 2) trpE and (lanes 3-5) 
trpE-gC (BHV-5) fusion proteins are marked with arrowheads. Immu- 
noblotting with MAb L6G (data not shown) revealed identical but 
weaker reactivity. 
fusion protein; its binding was substantially blocked by 
BHV-5 but not by BHV-1 virus absorption (Fig. 9). Con- 
versely, the bovine anti-BHV-1 antibody showed specific- 
ity to BHV-1 gO (aa 22-69)-specific fusion protein, and 
its reactivity was largely inhibited by BHV-1 but not by 
BHV-5 virus absorption (Fig. 9). These results indicated 
that the type-specific epitopes defined by BHV-1- and 
BHV-5-specific murine MAbs (F2 and 8B1/L6G, respec- 
tively) also are recognized by bovine antiserum against 
BHV-1 and BHV-5 in a type-specific manner. 
DISCUSSION 
The main purpose of this study was to analyze the 
molecular basis of antigenic diversity between the gC of 
BHV-1 and BHV-5. The BHV-5 gC sequence was deter- 
mined, and the predicted aa sequences of BHV-5 gC 
were compared with the BHV-1 gC sequences. Second, 
the location of linear type-specific antigenic determinants 
was identified in segments of the BHV-1 and BHV-5 gC 
ORFs by expressing genomic subfragments in E. coil and 
then determining MAb reactivity. 
Previous studies have located five linear (conforma- 
tional-independent) epitopes (I, II, III, VIII, and IX) on 
three separate domains of BHV-1 gC protein (Fitzpatrick 
eta/., 1990; Marshall etaL, 1988). Epitopes I, II, and III 
were mapped in domain II of gC between residues 22 
and 150 (Fitzpatrick et aL, 1990). The present results 
separate the boundaries of two of these three epitopes 
into discrete segments of domain II. The location of an 
epitope defined bythe neutralizing MAb F2 was mapped 
within the BHV-1 gC residues 22-69. A prominent hy- 
drophilic peak and several potential antigenic peaks 
are located within this region. Previously, the location 
of an epitope specified by the same MAb F2 (epitope 
IX) was reported to be within residues 140-240 (Fitzpa- 
trick et aL, 1990). These results clearly differ from our 
findings. Based on our data, this type-specific epitope 
is located at the amino-terminal region of the protein, 
which showed very little or no homology to the corre- 
sponding BHV-5 segment. However, residues 160-505 
(BHV-1 gC) showed considerable homology to the corre- 
sponding BHV-5 gC segment (aa 124-470). Thus, the 
BHV-l-specific linear epitope defined by MAb F2 proba- 
bly would not map in a highly conserved region of the 
two viruses. Consistent with this supposition is the find- 
ing that MAb F2 did not react to the fusion protein con- 
taining BHV-1 gC residues 173-336. 
[ ' , 
i f 
I 
~ ~ ~ 8B1 L6G 
I I I J 
r I 4- 4- 
I ' L -I- 4- 
I T i 4- 4- 
FIG. 8. Schematic representation of the BHV-5 gC glycoprotein and its segments that were expressed in pATH vectors. The BamHI/Afllll fragment 
containing the gO (BHV-5) ©RF is depicted on top, showing restriction endonuclease sites used for cloning in pATH plasmids (for details see 
Material and Methods), Glycoprotein segments expressed are shown as solid bars identified by aa numbers. A summary of the immunoreactivity 
of gO protein segments with MAbs 8B1 and L6G is shown on the table to the right, with (+) to denote reactivity and (-) for no reactivity. 
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FIG. 9. Type specificity of trpE-gC fusion proteins expressing the N-terminal 1-69 and 1-78 amino acids of BHV-1 and BHV-5 gO, respectively. 
(A) Coomassie blue-stained SDS-PAGE gel containing (lane 1) trpE, (lane 2) trpE-gC (BHV-1) 1 69, and (lane 3) trpE-gC (BHV-5) 1-78. Immunoblot- 
ting of the same proteins with (B) BHV-1 gC 1-69-specific MAb F2, (C) bovine anti-BHV-1 serum absorbed to BHV-5, (D) bovine anti-BHV-1 serum 
absorbed to BHV-1 and BHV-6, (E) BHV-5 gO 1-78-specific MAb 8B1, (F) bovine anti-BHV-5 serum absorbed to BHV-1, and (G) bovine anti-BHV-5 
serum absorbed to BHV-1 and BHV-5. The locations of trpE, trpE-gC (BHV-1) 1-69, and trpF-gC (BHV-5) 1-78 proteins are marked with arrowheads. 
BHV-1 gC aa residues 104-122 contained an epitope 
specified by neutralizing MAb 24. This segment contains 
one of the most prominent hydrophilic peaks of the BHV- 
1 gC aa sequence. A potential N-linked glycosylation site 
(aa residue 111) also is present within this segment. 
However, MAb 24 reacts very strongly to the virus glyco- 
protein as well as to E. co~i-expressed unglycosylated 
protein. Thus, it is likely that the epitope recognized by 
MAb 24 is glycosylation independent. 
BHV-5-specific MAbs 8B1 and L6G both recognized 
an epitope coding region containing BHV-5 gC residues 
31-78. This region contained two hydrophilic peaks and 
several potential antigenic peaks. One hydrophilic peak 
(aa 35-50) was the most prominent in the entire gC 
coding region. Considering the length of the region, these 
sequences could specify two distinct epitopes (MAbs 
8B1- and L6G-specific). 
These results are in agreement with the predicted 
aa sequence alignment data, because the aa se- 
quences at the amino-terminal segment of BHV-5 and 
BHV-1 gC are significantly different, and the BHV-1 
and BHV-5 gC-specific epitopes defined by the type- 
specific MAbs also mapped within the amino-terminal 
segment of the protein. Bovine antisera against BHV- 
1 and BHV-5 showed specificity to BHV-1 gC residues 
22-69 (MAb F2 epitope) and to BHV-5 gC residues 
31 -78 (MAb 8B1 ), respectively. The reactivity of MAbs 
F2 (BHV-1 gO-specific) and 8B1 (BHV-5 gO-specific) 
also has been consistent with several BHV-1 field iso- 
lates and two of three BHV-5 isolates from the United 
States (S. I. Chowdhury, unpublished data). Thus, the 
epitope coding sequences defined by MAbs F2 and 
8B1 appeared to be type specific. The presence of 
antibodies to these epitopes may be of diagnostic 
importance in discriminating between respiratory 
BHV-1 and neurovirulent BHV-5 infections in cattle. 
Several previous reports indicated that BHV-5 gO is 
slightly smaller than BHV-1 gO (Collins eta/., 1993; Friedli 
and Metzler, 1987). Consistent with these previous find- 
ings, it has been shown that the BHV-5 gC ORF is 50 aa 
shorter in length (471 aa) than the BHV-1 gO ORF (521 
aa). The carboxy-terminal two-thirds of the gC is well 
conserved between the two viruses. This includes the 
central region of gC (aa residues 172-323) that is re- 
ported to be the BHV-1 heparin-binding domain (Okazaki 
et aL, 1994). However, the carboxy-terminal hydrophilic 
region is considerably shorter in the BHV-5 sequences. 
Thus, the sequence differences at the amino- and the 
carboxy-terminal region, the absence of two putative gly- 
cosylation sites in the BHV-5, and the differences in the 
net charge of the amino-terminal regions of BHV-1 and 
BHV-5 gC could partially contribute to biological proper- 
ties of these two viruses, including the differential patho- 
genesis of respiratory and neurological disease. Future 
studies of BHV-1 and 5 gC should determine if such 
differences are functionally important in the pathogene- 
sis of respiratory and neurological diseases caused by 
these two viruses. 
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